Despite various treatment options such as androgen receptor-directed therapies, taxane-based chemotherapy, PSMA radioligand therapy, radium-223 and PARP inhibitors, prostate cancer in the castration-resistant situation takes a fatal course. This evidence concerns the gene FOLH1 and prostate cancer.